Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Steinbrecher D, et al. Among authors: bloehdorn j. Leuk Lymphoma. 2018 Jul;59(7):1614-1623. doi: 10.1080/10428194.2017.1390236. Epub 2017 Oct 24. Leuk Lymphoma. 2018. PMID: 29063805 Clinical Trial.
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A, Bloehdorn J, Hafner S, Bühler A, Seiler T, Kienle D, Winkler D, Bangerter M, Schlenk RF, Benner A, Lichter P, Döhner H, Stilgenbauer S. Kröber A, et al. Among authors: bloehdorn j. J Clin Oncol. 2006 Feb 20;24(6):969-75. doi: 10.1200/JCO.2005.03.7184. Epub 2006 Jan 17. J Clin Oncol. 2006. PMID: 16418492
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.
Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H. Edelmann J, et al. Among authors: bloehdorn j. Blood. 2012 Dec 6;120(24):4783-94. doi: 10.1182/blood-2012-04-423517. Epub 2012 Oct 9. Blood. 2012. PMID: 23047824 Free article.
Cellular origin and pathophysiology of chronic lymphocytic leukemia.
Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Dürig J, Küppers R. Seifert M, et al. Among authors: bloehdorn j. J Exp Med. 2012 Nov 19;209(12):2183-98. doi: 10.1084/jem.20120833. Epub 2012 Oct 22. J Exp Med. 2012. PMID: 23091163 Free PMC article.
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D. Weisser M, et al. Among authors: bloehdorn j. Blood. 2014 Jul 17;124(3):420-5. doi: 10.1182/blood-2013-12-538975. Epub 2014 Jun 10. Blood. 2014. PMID: 24916506 Free article. Clinical Trial.
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.
Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Hoster E, et al. Among authors: bloehdorn j. Leukemia. 2016 Jun;30(6):1428-30. doi: 10.1038/leu.2015.322. Epub 2015 Nov 24. Leukemia. 2016. PMID: 26598017 No abstract available.
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M. Lohmann G, et al. Among authors: bloehdorn j. Leukemia. 2017 May;31(5):1177-1186. doi: 10.1038/leu.2016.294. Epub 2016 Oct 24. Leukemia. 2017. PMID: 27773933
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S. Edelmann J, et al. Among authors: bloehdorn j. Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2. Leukemia. 2017. PMID: 27909343 Free PMC article. Clinical Trial. No abstract available.
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G. Kasenda B, et al. Among authors: bloehdorn j. Leukemia. 2017 Dec;31(12):2623-2629. doi: 10.1038/leu.2017.170. Epub 2017 May 31. Leukemia. 2017. PMID: 28559537 Clinical Trial.
Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A. Klymenko T, et al. Among authors: bloehdorn j. Leukemia. 2018 Feb;32(2):364-375. doi: 10.1038/leu.2017.255. Epub 2017 Aug 14. Leukemia. 2018. PMID: 28804121 Free PMC article.
44 results